ABSTRACT
Composite membrane as a flexible materials have found diverse applications in industrial and biomedical simultaneously, the recent studies have shown intrinsic improvement for membrane properties by inclusion of nanoparticles as a fillers with high portion ratio in inorganic polymers, the combination between two parts polymer and filler is as a result of collection the advantage of two component systems parts together. In this work, samples of polyvinyl alcohol (PVA)-nanoHaydroxyapatite (nHAp) composites were prepared by using casting method. The effects of addition of (nHAp) with different concentration on the optical properties of (PVA- nHAp) composite membrane have been studied by using wavelength range (220-820) nm. The absorption spectra, transmittance spectra, absorption coefficient, energy gap, refractive index, optical conductivity and extinction coefficient have been determined. The results show that the optical constants change with the increase of nHPA concentrations.
Subject(s)
Polyvinyl Alcohol , Spectrum Analysis , Chemistry Techniques, Synthetic , Nanoparticles , Materials Science , HydroxyapatitesABSTRACT
This is a prospective clinical study, in which we applied the modern risk stratification strategies, such as the TIMI risk score of. acute coronary syndrome, [Thrombolysis in myocardial infarction], associated with unstable angina and non-ST segment elevation. For this purpose, 188 Yemeni patients were followed up in Al-Gamhuria Teaching Hospital in Aden for 4 years from January 2004 to January 2008. According to the TIMI risk score of ACS, the investigated patients were divided into 3 subgroups: high, intermediate and low risk patients. Coronary angiography, performed in all patients, proved that the correlation between the coronary findings and the clinical risk status was reflecting the benefit of using clinical predictors for early diagnosis. We concluded that the application of the more detailed TIMI risk score was proved to be an effective tool not only for early prognosis, but also for designing therapeutic strategies in patients presented with symptoms of UA/NSTEML